Literature DB >> 17277640

The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach.

Charles E Argoff1.   

Abstract

The diagnosis and treatment of neuropathic pain may be complicated by comorbid conditions such as sleep disturbances, depression, and anxiety. The interrelationship between the index neuropathic pain state and these comorbidities is complex: comorbid conditions exacerbate pain, and in turn, pain exacerbates the comorbid conditions. Because comorbidities can negatively impact response to pain treatment, healthcare providers should assess comorbidities as part of the diagnostic work-up, and management strategies should be designed to treat the whole patient, not just the pain. Theoretically, therapies that not only reduce pain, but also improve sleep and reduce anxiety and depression can provide multiple benefits without the risk of increased side effects inherent in combination therapy. Anticonvulsants and antidepressants have demonstrated efficacy in improving neuropathic pain and positively impacting comorbid sleep and mood disturbances. Novel anticonvulsants that can address one or more comorbidities in addition to pain may represent viable treatment options for patients with neuropathic pain.

Entities:  

Mesh:

Year:  2007        PMID: 17277640     DOI: 10.1097/01.ajp.0000210945.27052.b3

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  46 in total

1.  Chronic pain and cigarette smoking and nicotine dependence among a representative sample of adults.

Authors:  Michael J Zvolensky; Katherine McMillan; Adam Gonzalez; Gordon J G Asmundson
Journal:  Nicotine Tob Res       Date:  2009-10-14       Impact factor: 4.244

2.  Chronic pain patients' treatment preferences: a discrete-choice experiment.

Authors:  Axel C Mühlbacher; Uwe Junker; Christin Juhnke; Edgar Stemmler; Thomas Kohlmann; Friedhelm Leverkus; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2014-06-21

3.  Different patterns of morphological changes in the hippocampus and dentate gyrus accompany the differential expression of disability following nerve injury.

Authors:  Eszter Kalman; Kevin A Keay
Journal:  J Anat       Date:  2014-10-01       Impact factor: 2.610

4.  Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model.

Authors:  Dou Yin; Yuan-Yuan Liu; Tian-Xiao Wang; Zhen-Zhen Hu; Wei-Min Qu; Jiang-Fan Chen; Neng-Neng Cheng; Zhi-Li Huang
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

5.  Neuropathic pain's biopsychosocial effects.

Authors:  Esra Dogru Huzmeli; Ismet Melek
Journal:  Neurol Sci       Date:  2017-08-19       Impact factor: 3.307

6.  Self-reported sleep duration associated with distraction analgesia, hyperemia, and secondary hyperalgesia in the heat-capsaicin nociceptive model.

Authors:  Claudia M Campbell; Sara C Bounds; Mpepera B Simango; Kenneth R Witmer; James N Campbell; Robert R Edwards; Jennifer A Haythornthwaite; Michael T Smith
Journal:  Eur J Pain       Date:  2010-12-30       Impact factor: 3.931

7.  Neuropathic pain in patients with Charcot-Marie-Tooth type 1A.

Authors:  Bogdan Bjelica; Stojan Peric; Ivana Basta; Ivo Bozovic; Aleksandra Kacar; Ana Marjanovic; Vukan Ivanovic; Marija Brankovic; Milena Jankovic; Ivana Novakovic; Vidosava Rakocevic Stojanovic
Journal:  Neurol Sci       Date:  2019-11-15       Impact factor: 3.307

8.  Daily sleep quality and mood as predictors of pain in children with juvenile polyarticular arthritis.

Authors:  Maggie H Bromberg; Karen M Gil; Laura E Schanberg
Journal:  Health Psychol       Date:  2011-08-15       Impact factor: 4.267

Review 9.  An Update on Repetitive Transcranial Magnetic Stimulation for the Treatment of Co-morbid Pain and Depressive Symptoms.

Authors:  Jonathan H Hsu; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Curr Pain Headache Rep       Date:  2018-06-14

10.  Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings.

Authors:  María Teresa Saldaña; Ana Navarro; Concepción Pérez; Xavier Masramón; Javier Rejas
Journal:  Rheumatol Int       Date:  2009-10-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.